#$%^&*AU2020201307A120200312.pdf#####Abuse-resistant controlled-release opioid dosage form Abstract The disclosure relates to oral controlled release pharmaceutical compositions comprising an opioid agonist, such as oxycodone hydrochloride, and an opioid antagonist, such as a pharmaceutically acceptable salt of naloxone, in a ratio of between 5:1 to 1:1, wherein the composition releases the oxycodone hydrochloride and pharmaceutically acceptable salt of naloxone.